Oxford Biomedica (LON:OXB) Posts Earnings Results

Key Points

• Oxford Biomedica reported a quarterly loss of GBX 30.39 per share, alongside a negative 17.85% net margin and negative 48.56% return on equity.
• Despite ongoing losses, the company’s first-half revenue rose 9% to £80.2 million, with 17 new client wins, and management maintained its full-year 2026 sales guidance.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average target price of GBX 580.85, although the shares remain well below their 52-week high of GBX 952.

Oxford Biomedica (LON:OXB - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported GBX (30.39) EPS for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 17.85% and a negative return on equity of 48.56%.

Oxford Biomedica Stock Performance

Shares of LON:OXB opened at GBX 481.50 on Wednesday. The business's fifty day moving average price is GBX 515.68 and its two-hundred day moving average price is GBX 577.12. Oxford Biomedica has a fifty-two week low of GBX 420 and a fifty-two week high of GBX 952. The stock has a market capitalization of £582.85 million, a price-to-earnings ratio of -17.89 and a beta of 1.09. The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67.

Key Stories Impacting Oxford Biomedica

Here are the key news stories impacting Oxford Biomedica this week:

• Positive Sentiment: Revenue growth and new business wins: Oxford Biomedica reported first-half revenue of £80.2 million, up 9%, while securing 17 new clients—a record for the company. The wins suggest continued demand for its cell and gene therapy development and manufacturing services. Oxford Biomedica delivers solid H1 growth, record commercial wins
• Positive Sentiment: Full-year guidance maintained: Management reiterated its sales outlook for 2026, reducing the risk of a near-term guidance downgrade and indicating confidence in the company’s growth pipeline. Oxford Biomedica H1 Revenue Reaches £80.2 Million as FY2026 Guidance Maintained
• Positive Sentiment: Operational modernization: Oxford Biomedica is advancing a global quality transformation using Veeva Quality Cloud, which could improve consistency, compliance and efficiency across its operations. Oxford Biomedica Advances Global Quality Transformation with Veeva Quality Cloud
• Neutral Sentiment: Analyst interest remains constructive: A pre-results valuation analysis identified potential upside, although this is an external estimate rather than company guidance and does not remove execution risk. Earnings To Watch: Oxford BioMedica PLC Q2 2026
• Negative Sentiment: Losses remain the key concern: Oxford Biomedica reported quarterly EPS of negative GBX30.39, with a 17.85% net loss margin and a negative 48.56% return on equity. The half-year loss widened, overshadowing revenue growth and client additions. Oxford Biomedica reiterates sales outlook but half-year loss widens

Analyst Upgrades and Downgrades

OXB has been the subject of several recent analyst reports. Royal Bank Of Canada reaffirmed an "outperform" rating and set a GBX 900 price objective on shares of Oxford Biomedica in a report on Tuesday, September 1st. Jefferies Financial Group reissued a "buy" rating and issued a GBX 8.27 price objective on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a GBX 595 price objective on shares of Oxford Biomedica in a research note on Wednesday, September 2nd. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of GBX 580.85.

Oxford Biomedica Company Profile

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.